DK0443891T3 - Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen - Google Patents
Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringenInfo
- Publication number
- DK0443891T3 DK0443891T3 DK91400163.1T DK91400163T DK0443891T3 DK 0443891 T3 DK0443891 T3 DK 0443891T3 DK 91400163 T DK91400163 T DK 91400163T DK 0443891 T3 DK0443891 T3 DK 0443891T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical
- phenylalanine
- diseases
- treatment
- myristotyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 title 2
- 230000007498 myristoylation Effects 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- GFNNQTYRJPFJGX-NRFANRHFSA-N (2s)-3-phenyl-2-(tetradecanoylamino)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GFNNQTYRJPFJGX-NRFANRHFSA-N 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9000834A FR2657259A1 (fr) | 1990-01-25 | 1990-01-25 | Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0443891T3 true DK0443891T3 (da) | 1993-12-27 |
Family
ID=9393082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91400163.1T DK0443891T3 (da) | 1990-01-25 | 1991-01-25 | Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5164414A (show.php) |
| EP (1) | EP0443891B1 (show.php) |
| JP (1) | JPH0717503B2 (show.php) |
| AT (1) | ATE94387T1 (show.php) |
| AU (1) | AU633395B2 (show.php) |
| CA (1) | CA2034861A1 (show.php) |
| DE (1) | DE69100364T2 (show.php) |
| DK (1) | DK0443891T3 (show.php) |
| ES (1) | ES2060310T3 (show.php) |
| FR (1) | FR2657259A1 (show.php) |
| IE (1) | IE65573B1 (show.php) |
| OA (1) | OA09478A (show.php) |
| PT (1) | PT96571A (show.php) |
| ZA (1) | ZA91574B (show.php) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672598A1 (fr) * | 1991-02-11 | 1992-08-14 | Adir | Nouveaux inhibiteurs de n-myristoyltransferase, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5859052A (en) * | 1993-01-14 | 1999-01-12 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US5599947A (en) * | 1993-01-14 | 1997-02-04 | G. D. Searle & Co. | Fatty acid analogs and prodrugs |
| US6407125B1 (en) | 1995-12-29 | 2002-06-18 | Novactyl, Inc. | Pharmacological agent and method of treatment |
| US6127393A (en) * | 1995-12-29 | 2000-10-03 | Novactyl, Inc. | Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method |
| US6579891B1 (en) | 1995-12-29 | 2003-06-17 | Novactyl, Inc. | Agent and method for prevention and treatment of cancer in animals |
| US6743771B2 (en) | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| US6441009B1 (en) | 1998-08-01 | 2002-08-27 | Novactyl, Inc. | Agent and method of preventing and treating heavy metal exposure and toxicity |
| CA2388754C (en) * | 1999-10-13 | 2010-07-13 | Marco A. Chacon | Therapeutic intervention to mimic the effect of caloric restriction |
| US6403618B1 (en) | 2000-02-15 | 2002-06-11 | Novactyl, Inc. | Agent and method for controlling angiogenesis |
| AU2002318427A1 (en) * | 2001-06-25 | 2003-03-03 | University Of Massachusetts | N-fatty acid-amino acid conjugates and therapeutic uses |
| DE10353806A1 (de) * | 2003-11-14 | 2005-07-07 | Bundesrepublik Deutschland, vertreten durch das Bundesministerium für Gesundheit, dieses vertreten durch das Robert-Koch-Institut, vertreten durch seinen Präsidenten | Verwendung von Aminosäure- und Zucker-Amphiphilen zur Inaktivierung von lipidumhüllten Viren |
| US7544714B2 (en) * | 2004-07-16 | 2009-06-09 | University Of Massachusetts | Lipid-amino acid conjugates and methods of use |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| ES2937269T3 (es) | 2011-07-22 | 2023-03-27 | Pacylex Pharmaceuticals Inc | Letalidad sintética y el tratamiento del cáncer |
| EP2830437B1 (en) | 2012-03-30 | 2018-12-26 | Givaudan SA | N-acylated 1-aminocycloalkyl carboxylic acids as food flavouring compounds |
| JP6224072B2 (ja) | 2012-03-30 | 2017-11-01 | ジボダン エス エー | フレーバープロフィール食用組成物の改良のためのｎ−アシル−アミノ酸誘導体 |
| US10711230B2 (en) | 2012-03-30 | 2020-07-14 | Givaudan Sa | N-acyl proline derivatives as food flavoring compounds |
| BR112014023905B1 (pt) | 2012-03-30 | 2021-07-13 | Givaudan Sa | Composições de sabor e comestíveis compreendendo derivados de metionina n-acilados e bebida calórica e não-calórica |
| WO2013148991A1 (en) | 2012-03-30 | 2013-10-03 | Givaudan S.A. | N-acyl derivatives of gamma amino - butyric acid and and beta alanine as food flavouring compounds |
| US10836712B2 (en) | 2012-03-30 | 2020-11-17 | Givaudan S.A. | Organic compounds |
| US10582715B2 (en) | 2012-03-30 | 2020-03-10 | Givaudan Sa | Powder flavour composition |
| CA2890113C (en) * | 2012-10-30 | 2023-01-17 | Pacylex Pharmaceuticals Inc. | Synthetic lethality and the treatment of cancer |
| WO2015050535A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan S.A. | Organic compounds |
| EP3052472B1 (en) | 2013-10-02 | 2019-02-27 | Givaudan S.A. | N-acylated 2-aminoisobutyric acid compounds and flavour compositions containing them |
| US10674755B2 (en) | 2013-10-02 | 2020-06-09 | Givaudan S.A. | Organic Compounds |
| WO2015048990A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan Sa | Organic compounds having taste-modifying properties |
| US10834950B2 (en) | 2013-10-02 | 2020-11-17 | Givaudan S.A. | Organic compounds |
| WO2015048991A1 (en) | 2013-10-02 | 2015-04-09 | Givaudan Sa | Organic compounds having taste-modifying properties |
| US10537127B2 (en) | 2013-10-02 | 2020-01-21 | Givaudan S.A. | Organic compounds |
| GB201317424D0 (en) | 2013-10-02 | 2013-11-13 | Givaudan Sa | Improvements in or relating to organic compounds |
| EP3325662B1 (en) | 2015-07-17 | 2023-08-30 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778878A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides I |
| US4778877A (en) * | 1986-08-07 | 1988-10-18 | Washington University | Novel inhibitor peptides II |
-
1990
- 1990-01-25 FR FR9000834A patent/FR2657259A1/fr active Granted
-
1991
- 1991-01-24 PT PT96571A patent/PT96571A/pt not_active Application Discontinuation
- 1991-01-24 JP JP3007188A patent/JPH0717503B2/ja not_active Expired - Lifetime
- 1991-01-24 IE IE24291A patent/IE65573B1/en not_active IP Right Cessation
- 1991-01-24 CA CA002034861A patent/CA2034861A1/fr not_active Abandoned
- 1991-01-24 US US07/645,124 patent/US5164414A/en not_active Expired - Fee Related
- 1991-01-25 EP EP91400163A patent/EP0443891B1/fr not_active Expired - Lifetime
- 1991-01-25 AT AT91400163T patent/ATE94387T1/de active
- 1991-01-25 AU AU69987/91A patent/AU633395B2/en not_active Ceased
- 1991-01-25 OA OA59940A patent/OA09478A/xx unknown
- 1991-01-25 DK DK91400163.1T patent/DK0443891T3/da active
- 1991-01-25 ES ES91400163T patent/ES2060310T3/es not_active Expired - Lifetime
- 1991-01-25 DE DE91400163T patent/DE69100364T2/de not_active Expired - Fee Related
- 1991-01-25 ZA ZA91574A patent/ZA91574B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69100364T2 (de) | 1994-04-21 |
| ATE94387T1 (de) | 1993-10-15 |
| US5164414A (en) | 1992-11-17 |
| EP0443891B1 (fr) | 1993-09-15 |
| OA09478A (fr) | 1992-11-15 |
| ES2060310T3 (es) | 1994-11-16 |
| PT96571A (pt) | 1991-10-15 |
| AU6998791A (en) | 1991-08-01 |
| IE65573B1 (en) | 1995-11-01 |
| AU633395B2 (en) | 1993-01-28 |
| FR2657259B1 (show.php) | 1994-08-19 |
| ZA91574B (en) | 1991-11-27 |
| FR2657259A1 (fr) | 1991-07-26 |
| DE69100364D1 (de) | 1993-10-21 |
| JPH0717503B2 (ja) | 1995-03-01 |
| IE910242A1 (en) | 1991-07-31 |
| CA2034861A1 (fr) | 1991-07-26 |
| EP0443891A1 (fr) | 1991-08-28 |
| JPH04210916A (ja) | 1992-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0443891T3 (da) | Anvendelse af N-myristotyl-(S)-phenylalanin eller et additionssalt deraf med en farmaceutisk acceptabel base til opnåelse af et farmaceutisk middel og farmaceutisk middel til behandling af sygdomme ved indgribning i myristoyleringen | |
| NO894296D0 (no) | Fremgangsmaate for behandling av leddgikt og betennelsessykdommer. | |
| DE59101397D1 (de) | O-glycosyliertes ifn-alpha. | |
| CA2083179A1 (en) | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use | |
| ES2056180T3 (es) | Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina. | |
| ES2071663T3 (es) | Analogo de fluoxetina. | |
| NO931413D0 (no) | Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer | |
| ES2120962T3 (es) | Composicion antivirica. | |
| DK160816C (da) | Benzoyl-urinstof-derivater, fremgangsmaade til fremstilling af disse, fremgangsmaade til bekaempelse af insektangreb samt insekticidt middel indeholdende disse | |
| IT9020968A0 (it) | Metodi e composizioni farmaceutiche per il trattamento di malattie oftalmiche | |
| DK627289D0 (da) | Anvendelse af bicyclononanderivater | |
| NO913117L (no) | Fremgangsmaate for behandling av benoedeleggende sykdommer. | |
| DE59104783D1 (de) | Patientenuntersuchungstisch. | |
| FI911533A7 (fi) | Bentsoksatsiini-johdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö sairauksien hoitamiseen tai ennalta ehkäisemiseksi | |
| DK632388A (da) | Pharmaceutisk middel til behandling af hyperlipidaemi hol pattedyr | |
| SE9000948D0 (sv) | New use | |
| MX9102325A (es) | Formas de dosis farmaceuticas de almacalante y procedimiento para su obtencion. | |
| ATE164066T1 (de) | Neue pharmazeutische formulierungen von 5-(2- chlor-1-hydroxyethyl)-4-methylthiazol | |
| NO960347D0 (no) | Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF | |
| NL7803642A (nl) | Individuele endo-osseo inplant voor odonto-stomalogie (mondchirurgie) en werkwijze voor de snelle en perfek- te aanbrenging van de inplant in de patient. | |
| DK670588D0 (da) | Farmaceutisk praeparat til behandling af phlebektasi og fremgangsmaade til fremstilling af praeparatet | |
| SE8702227D0 (sv) | New use | |
| IT7829846A0 (it) | Composizione farmaceutica per la cura della sordita' e del ronzio auricolare. | |
| DK305289A (da) | Apparat til behandling af reumatiske sygdomme | |
| NO923078D0 (no) | Skumbar sammensetning for farmasoeytisk anvendelse, anvendelse derav og fremgangsmaate for behandling |